ExplorePopulationMultiple Myeloma Patients
Population

Multiple Myeloma Patients

Also known as: Multiple Myeloma Patients MM
3 findings 1 paper 4 related entities View in graph →

Related entities

interventions
conditions
outcomes
studys

Findings (27)

None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01
None
decline

Multiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins

Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)

Size: HR 1.16 (EDIR); HR 1.17 (EDIH) CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01

Papers (1)